About us
This is Medinsa
We consider ourselves a competent and versatile player in the production of highly effective and sophisticated pharmaceuticals. The numerous pharmaceutical forms that make up our diverse portfolio include film-coated, orally disintegrating and effervescent tablets, multiparticulate pharmaceutical forms (MUPS) and various capsule formulations.
In addition to our expertise in pharmaceutical manufacturing, we set ourselves apart from the competition with know-how in product development, analytics and customer-focused order management.
We stand for excellence and expertise – from product development and manufacturing to packaging and final shipment of goods.
Our role within the Aristo Pharma Group
Aristo Pharma was founded in 2008 from the merger of various traditional German pharmaceutical companies, some of whose roots go back to 1875. Today, Aristo Pharma's core business is the production and distribution of sought-after active ingredients in the generics market, which are usually marketed under their own brand. The independent production sets the group apart from most German pharmaceutical suppliers. In addition, the broad range of prescription and over-the-counter medicines extends from tried-and-tested herbal medicines to modern medical products and aids.
The composition of the Aristo Pharma Group is as diverse as its product portfolio: In addition to the company headquarters in Berlin, the group comprises five production sites – in Hilden, Wernigerode, twice in the German capital Berlin and in Madrid - as well as its own logistics centre in Osterweddingen. This makes Aristo Pharma stand out as one of the few suppliers in Germany that manufacture their medicines predominantly in Germany or Europe.
Together with the 14 distribution sites throughout Europe, the company can draw on the know-how of more than 1,600 employees. They all make a valuable contribution to the success of the Aristo Pharma Group's mission: the reliable and affordable supply of high-quality medicines.
As Aristo Pharma's first production site outside Germany, Medinsa underlines the international orientation of the entire group of companies. Our outstanding expertise lies in the production and development of medicinal products with modified release of active ingredients. Exemplary for this is the advanced pilot plant of drug development. Here, we can easily and safely scale up from small-scale production to large-scale industrial production.
Medinsa in pictures
Our site
A look behind the scenes at Medinsa
Medinsa then and now
Our history
In 1972, Laboratorios Andrómaco, founded in Madrid, relocated to Torrejón de Ardoz. The new pharmaceutical plant later became Medinsa. The initial products included throat lozenges and Pepticum (omeprazole capsules). Seven years later, Grünenthal GmbH bought 40 per cent of the company’s shares.
In 1988, products for third-party customers were manufactured at the site for the first time. In 1993, all the shares of Andrómaco were acquired by Grünenthal.
Medinsa was officially founded in 1999. The Spanish subsidiary of the Grünenthal Group now focused on the development and manufacturing of oral pharmaceutical forms. In 2004, a modernisation and expansion process began, which took several years. This process was overseen by Joachim Teubner, who is still the Managing Director of Medinsa today.
Laboratorios Andrómaco 1974
In 2011, after the completion of the modernisation works, the site was taken over by Aristo Pharma. Two years later, the company made a groundbreaking investment in the production of pellets.
In 2018, the company premises were expanded by 2,000 square metres. This resulted in a modern, fully air-conditioned finished goods warehouse, from which Medinsa’s customers are supplied today.
In 2021, a new wastewater treatment plant was installed to meet the global goal of sustainable development and production.
In 2022/2023, Medinsa installed a photovoltaic system with an installed capacity of 600 kWp, which currently covers 20 per cent of the energy demand.
how we work and operate
Our mission
Medinsa’s objective is clear and unequivocal: the production and development of high-quality, affordable pharmaceuticals that are an essential part of basic medical care. The way we conduct our business reflects our practiced values of integrity, commitment, respect, quality and excellence.
Sustainability is important to us, which is why we focus on the following aspects: Our staff, our customers and suppliers, our community, our environment, correct and transparent corporate governance.
As a future-oriented pharmaceutical company, we are committed to conducting our business in a way that minimises and controls environmental, health and safety risks. Our company is ISO 14001:2015 and ISO 45001:2018 certified and holds the independent BCorp sustainability certification.
Guidelines, principles and values
Our Code of Ethics
With the aim of achieving sustainable success, at Medinsa we have the firm belief that our culture of ethics and compliance are key elements for the development of our activity.
Our Ethical Code applies to all Medinsa collaborators, suppliers and clients and it encompasses behavioural principles for the company’s internal relationships and its relationships with interest groups and goes beyond regulatory compliance.
Our sustainability report
In our second annual Sustainability Report (EINF), we present the progress and achievements of Laboratorios Medicamentos Internacionales, S.A.U (Medinsa) with regard to environmental, ethical and social objectives.
The report offers our company the opportunity to show how we integrate our values of integrity, excellence and respect for people in all our activities and how we contribute to the accessibility and universality of the healthcare system.
At Medinsa, we work hard to advance fundamental aspects that are part of our DNA and must guide our operations. Among them are care, respect and promotion of the professional development of our employees, promoting values such as diversity and inclusion; compliance with our code of conduct and all policies and procedures derived from it; and active listening to our interest groups, all through dialogue channels that allow shared vision and value in our relationships.
View Medinsas sustainability report
